A recent report by Credit Suisse analysts found that investing in medical nanotechnology could have a real payoff in the coming years. Oncology and CNS diseases in particular will be a target for nanotech drug developers, which include, Flamel Technologies, Sandvik and Orthovita. Intellectual property and the attitudes of agencies faced with regulating nanotech trials will prove to be challenges, however. Report